It has been shown that the eraser FTO acts as an m6A demethylase to promote melanoma tumorigenesis and induce resistance of tumor cells to anti-PD-1 therapy, and moreover, the combination of FTO inhibition and anti-PD-1 blockade may synergistically reduce melanoma resistance to immunotherapy (Yang et al., 2019). This evidence concerns the gene FTO and neoplasm.